Last reviewed · How we verify
NCT00898963
Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
trial testing gene expression analysis in Lymphoma in 175 participants. Completed in 11 February 2011.
11 February 2011
Quick facts
| Lead sponsor | ECOG-ACRIN Cancer Research Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 175 |
| Start date | 18 April 2007 |
| Primary completion | 11 February 2011 |
| Estimated completion | 11 February 2011 |
Drugs / interventions tested
- gene expression analysis
- microarray analysis
- polymorphism analysis
- diagnostic laboratory biomarker analysis
- immunohistochemistry staining method
- immunologic technique
Conditions studied
- Lymphoma — all drugs for Lymphoma →
Sponsor
ECOG-ACRIN Cancer Research Group
Who can join
Adults 18 to 120, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00898963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of gene expression analysis
Trials testing the same drug.
- NCT01567722 — Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies · terminated
- NCT01381705 — Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma · completed
- NCT01209299 — Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated Wi · completed
- NCT01487733 — Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and E · completed
- NCT01505712 — Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial · completed
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
- NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting
Other ECOG-ACRIN Cancer Research Group trials
Trials by the same sponsor.
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting
- NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting
- NCT06084845 — Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for P · Phase 2 · withdrawn
- NCT06319027 — Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Tr · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00898963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group
- Last refreshed: 31 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00898963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing